Valuation will be determined by nothing but upcoming licensing and partnership with no other Than big pharma in major markets, if the futility analysis yields positive results and a continuation Of the betonmace trial I guarantee some bp will step up to the plate to partner Maybe a certified value rights deal or buyout assuming EMA and FDA approval Of Rvx 208, which will be a rubber stamp ino with a successful betonmace trial What the price will be will be determined by past buyouts of biotech in the same space I have done the research but If peaks sales are 5 billion for say 12 years One can sumise Rvx will be bought for say 10% of 50bill?? Til then we will move up on big news that has been listed many times, A regional deal should get us past $2.67, or a Nasdaq Listing will get is higher Don release the hounds on good news